Santé et pharmacie en Iran

Guide pratique sur santé et pharmacie en iran pour les investisseurs étrangers : cadre, opportunités, chiffres et voies d'entrée.

Healthcare and pharmaceuticals in Iran — Health care in Iran

Health care in Iran

Chiffres clés

Domestic drug supply
≈95% of volume produced locally
Biotech strength
Biosimilars, vaccines
Import gap
Devices, diagnostics, novel therapeutics
Regulator
Iran Food and Drug Administration
Medical tourism
Established regional inbound flow
Payer mix
Public insurance and out-of-pocket

Aperçu

L'analyse détaillée ci-dessous est publiée en anglais.

Iran manufactures the large majority of the medicines it consumes by volume and has built biotech capability in biosimilars and vaccines that is unusual for the region.

The import gap is in high-value therapeutics, advanced medical devices and diagnostics — precisely where a foreign technology partner adds capability rather than competing with domestic producers.

Regulatory pathway

The Iran FDA controls registration, pricing and import licensing for medicines and devices. Registration timelines depend heavily on whether an equivalent domestic product exists — protection of local manufacture is an explicit policy objective.

Local manufacturing or fill-finish partnerships shorten market access considerably compared with a pure import registration.

Devices and diagnostics

Imaging, laboratory automation, interventional cardiology and oncology equipment are consistently import-dependent, with service and consumables representing the durable revenue rather than the capital sale.

Distributor selection is the main commercial risk: after-sales service capability, not price, determines whether an installed base grows.

Medical tourism

Iran receives significant inbound medical travel from neighbouring countries for surgery, fertility treatment and ophthalmology, driven by cost and clinical reputation.

Investment opportunities lie in hospital capacity, accredited private clinics and the hospitality and coordination layer around them.

Questions fréquentes

How much of Iran's medicine is produced domestically?

Around 95% by volume, though a disproportionate share of value sits in imported high-end therapeutics.

Who regulates pharmaceuticals and devices in Iran?

The Iran Food and Drug Administration, which controls registration, pricing and import licensing.

What is the fastest route to market for a foreign pharma company?

Local manufacturing, licensing or a fill-finish partnership with a registered domestic producer, which typically clears faster than import-only registration.

Is medical tourism an investable segment?

Yes. Established regional inbound flows support investment in accredited private clinics, hospital capacity and the coordination layer around treatment.

Discutez de ce sujet avec nos conseillers

Nous accompagnons les investisseurs étrangers : entrée sur le marché, licences et structuration en Iran.

Nous contacter